Summary of published, peer-reviewed findings
Valkee Oy (April 2015)

Research efforts at Valkee follow a two-fold focus: Showing clinical effectiveness of the treatment while at the same time investigating the underlying mechanism of action of transcranial bright light.

The following results have been published in international, peer-reviewed journals:

1. Transcranial bright light treatment via ear canals in seasonal affective disorder: a randomized controlled double-blind dose-response study

Authors: Jurvelin H, Takala T, Nissilä J, Timonen M, Rüger M, Jokelainen J, Räsänen P

Summary:
In a 4 week trial, 89 patients suffering from SAD were randomly assigned to one of three treatment groups and received either a low (1 lumen), medium (4 lumen), or high dose (9 lumen) of daily bright light in the ear for 12 minutes in the morning. Depressive symptoms and cognitive performance were assessed using standard psychiatric instruments such as the Beck Depression Inventory (BDI) and the Trial Making Test (TMT) at the beginning, during, and at the end of the trial. The results showed a significant, at least 50% reduction of depressive symptoms in 74-79% of the patients according to the BDI in all three treatment groups as well as a significant improvement of cognitive performance compared to baseline.

2. Transcranial bright light exposure via ear canals does not suppress nocturnal melatonin in healthy adults--a single-blind, sham-controlled, crossover trial.

Authors: Jurvelin H, Takala T, Heberg L, Nissilä J, Rüger M, Leppäluoto J, Saarela S, Vakkuri O.

Summary:
The present study investigated the effects of transcranial bright light (TBL) on melatonin and cortisol secretion in healthy volunteers. 8 subjects (3F, 5M; mean age ± SD: 27± 5 yrs) were exposed to TBL during the night-time in a randomized, placebo controlled study design. Subjects reported to the laboratory in the evening (21 h) and were subjected to the same light/dark rhythm in both conditions (16L:8D; lights off at 23 h, lights on at 07 h) prior to the TBL or placebo exposure form 01:10-01:34 h. Saliva and urine samples for melatonin and cortisol were collected at noon, 18, 21, 22, 23, midnight, 01, 02, 03, 06, 07, 08, and 09h. Results clearly showed that neither melatonin or cortisol secretion nor the circadian rhythm of both endocrine markers was affected by the nocturnal exposure to TBL compared to placebo. This is in line with recent findings showing no melatonin suppression due to TBL exposure in the late evening (Bromundt et al., 2013).
3. Effects of bright light treatment on psychomotor speed in athletes.

Authors: Tulppo MP, Jurvelin H, Roivainen E, Nissilä J, Hautala AJ, Kiviniemi AM, Kiviniemi VJ, Takala T.

Summary:
Recent fMRI findings suggested that transcranial bright light (TBL) might have physiological effects on brain functions in humans. The present study investigated if TBL treatment was able to improve psychomotor speed in professional ice hockey players in a randomized, placebo controlled design. A total of 22 pro hockey players (N=11 TBL group; N=11 placebo group; overall mean age ± SD: 25 ±5 yrs) received either 12 min of TBL or placebo every morning between 8 and noon for a period of 24 days. Psychomotor speed using a visual warning signal paradigm was tested before and after trial completion and data were analyzed for mean reaction time and mean motor time. Results showed that psychomotor speed, particular motor time, improved after 24 days of TBL treatment compared to placebo in a group of professional ice hockey players.


Summary:
In this initial pilot study, 13 SAD patients were subjected to a daily dose of 8-12 min. of transcranial bright light therapy for 3 weeks. Depressive and anxiety symptoms were measured using standard questionnaires such as the 17-item Hamilton Depression Rating Scale (HAMD-17), the Beck Depression Inventory-21 (BDI), and the 14-item Hamilton Anxiety Rating Scale (HAMA) prior to the 4 week trial and afterwards. When comparing the depression and anxiety score between week zero (baseline) and week 4 (study endpoint), results showed a significant reduction in reported symptoms on all three measures. The findings suggest that transcranial bright light therapy might be an alternative to the traditional light therapy and should be explored in more depth.

5. Stimulating brain tissue with bright light alters functional connectivity in brain at the resting state.

Journal link:
Summary:
50 healthy subjects were randomized into two groups (N=24 experimental group, N=26 control group) and either received 12 min of transcranial bright light therapy or sham, i.e. no light, while being subjected to Functional Magnetic Resonance Imaging (fMRI). The results of the fMRI showed a clear increase in neural connectivity of the visual cortex and sensorimotor areas of the cortex under the transcranial light compared to the sham group. This suggests the brain to be light perceptive. In addition, these were the same brain areas that showed increased connectivity in the studies by Abou-Elseoud et al. (2011; 2014), summarized below.


Summary:
Resting state functional brain activity provides a method to detect an existing neurobiological substrate for various disorders, including Seasonal Affective Disorder (SAD). For this purpose, a total of 90 subjects (45 SAD patients; 45 healthy controls) underwent an fMRI to determine functional connectivity of various brain areas in the resting state. A total of 47 resting state networks (RSNs) were investigated. The results showed a clear difference in functional connectivity between SAD patients and healthy, age, gender and ethnicity-matched controls in 11 out of the 47 tested RSNs. The SAD patients showed increased functional connectivity in attentional, visual, and sensorimotoric RSNs. These findings support previous findings of psychomotor, attentional, and cognitive impairments seen in SAD patients. Interestingly enough, the same brain areas showed increased activity in healthy controls when exposed to TBL in the previous study.

Authors: Abou-Elseoud A, Littow H, Remes J, Starck T, Nikkinen J, Nissilä J, Timonen M, Tervonen O, Kiviniemi V.

Summary:
90 subjects (45 SAD patients; 45 healthy controls) underwent a fMRI to determine functional connectivity of brain areas. Results from the fMRI scans were analyzed with different mathematical models. In addition to increased neuronal connectivity within the visual and sensorimotor cortex of the SAD patients, results showed that depending on the model order and analysis, the sensitivity towards disease detection can be significantly improved and resting state brain activity might prove to be a very useful tool to detect the underlying neurobiological substrates of diseases.

8. Encephalopsin (OPN3) protein abundance in the adult mouse brain.

Authors: Antti Flyktman, Satu Mänttäri, Juuso Nissilä, Markku Timonen and Seppo Saarela

Summary:
Light exposure via ear canals has a significant effect on brain encephalopsin expression and plasma and adrenal gland monoamine production in blind mice.

10. Transcranial Bright Light and Symptoms of Jet Lag: A Randomized, Placebo-Controlled Trial.

Authors: Jurvelin, Heidi; Jokelainen, Jari; Takala, Timo
Journal: Aerospace Medicine and Human Performance, Volume 86, Number 4, April 2015, pp. 344-350(7)

Summary:
Rapid travel over multiple time zones usually results in transient desynchronization between environmental time and the biological clock of the individual. Common symptoms are increased daytime sleepiness, reduced sleep duration and quality, and performance impairments. Exposure to ocular bright light is known to alleviate jet lag symptoms and facilitate adaptation to a new time zone. Recently, transcranial bright light (TBL) via the ear canals has been shown to have antidepressant, anxiolytic, and psychomotor performance-enhancing effects. The group studied whether intermittent TBL exposure can alleviate jet lag symptoms in a randomized, double-blind, placebo-controlled study, and found a significant reduction of overall jet lag symptoms (VAS), subjective sleepiness (KSS), and the fatigue, inertia, and forgetfulness subscales of the POMS when comparing the active TBL treatment group (N = 30) to the placebo group (N = 25).